Tacrolimus Ointment 0.1% “Iwaki”: Key Information, Including Pharmacological Classification, Side Effects and Package Insert | Nikkei Medical Prescription Drug Encyclopedia

This article focuses on key information about Tacrolimus Ointment 0.1% “Iwaki,” including that its mechanism of action improves skin symptoms such as atopic dermatitis through immunosuppressive activity. The package insert lists atopic dermatitis among the indicated conditions and states that adults should apply an appropriate amount to the affected area 1–2 times daily, with no more than 5 g applied per application.

Regarding precautions related to dosage and administration, the package insert states that blood concentrations may increase during periods of worsening rash, that use should be discontinued if no improvement is observed, that application should be continued only as needed even after symptoms improve, and that applications should be approximately 12 hours apart when the medicine is applied twice daily.

The package insert covers precautions including contraindications, warnings and drug interactions. It specifically states that the medicine should not be used on sites other than the affected area, that concomitant use with PUVA therapy or other ultraviolet therapies should be avoided, and that restrictions and precautions apply to pregnant or breastfeeding women and children. Use should be avoided in patients with severe renal impairment, hyperkalemia or skin infections. Information on the risk of carcinogenicity with long-term use and the importance of avoiding sunlight exposure are also emphasized.

The medicine should be stored at room temperature. Information from overseas epidemiological data and animal studies is also provided regarding the assessment of long-term carcinogenic risk. The article states that this clinical-use information should be prescribed and administered by physicians under appropriate supervision.